Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanara MedTech (SMTI) Accumulated Expenses (2016 - 2025)

Sanara MedTech (SMTI) has disclosed Accumulated Expenses for 15 consecutive years, with $10.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Accumulated Expenses rose 31.72% year-over-year to $10.9 million, compared with a TTM value of $10.9 million through Sep 2025, up 31.72%, and an annual FY2024 reading of $2.3 million, down 70.49% over the prior year.
  • Accumulated Expenses was $10.9 million for Q3 2025 at Sanara MedTech, up from $3.0 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $10.9 million in Q3 2025 and bottomed at $187875.0 in Q1 2021.
  • Average Accumulated Expenses over 5 years is $4.4 million, with a median of $3.1 million recorded in 2022.
  • Peak annual rise in Accumulated Expenses hit 112461.98% in 2021, while the deepest fall reached 84.67% in 2021.
  • Year by year, Accumulated Expenses stood at $1.0 million in 2021, then soared by 647.29% to $7.8 million in 2022, then decreased by 1.05% to $7.7 million in 2023, then crashed by 70.49% to $2.3 million in 2024, then soared by 380.14% to $10.9 million in 2025.
  • Business Quant data shows Accumulated Expenses for SMTI at $10.9 million in Q3 2025, $3.0 million in Q2 2025, and $8.2 million in Q1 2025.